Last reviewed · How we verify
C213 Microneedle System — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
C213 Microneedle System (C213 Microneedle System) — Zosano Pharma Corporation. Transdermal microneedle array that delivers drug compounds through the skin for rapid systemic absorption.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| C213 Microneedle System TARGET | C213 Microneedle System | Zosano Pharma Corporation | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- C213 Microneedle System CI watch — RSS
- C213 Microneedle System CI watch — Atom
- C213 Microneedle System CI watch — JSON
- C213 Microneedle System alone — RSS
Cite this brief
Drug Landscape (2026). C213 Microneedle System — Competitive Intelligence Brief. https://druglandscape.com/ci/c213-microneedle-system. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing